Cargando…

P1151: METABOLIC TUMOR VOLUME IMPROVES OUTCOME PREDICTION IN UNTREATED MANTLE CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Vergote, V. K., Verhoef, G., Janssens, A., Woei-a-jin, F. S., Laenen, A., Tousseyn, T., Dierickx, D., Deroose, C. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431357/ http://dx.doi.org/10.1097/01.HS9.0000847472.18815.c3

Ejemplares similares

1151. Clinical Characteristics of Persistent Staph Aureus Bacteremia in Children
por: Venturelli, Nicholas, et al.
Publicado: (2021)

P1151: BENDAMUSTINE-CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
por: Garcia-Calvo, Gloria Ines Iacoboni, et al.
Publicado: (2023)

1151. Candida Colonization Alters Pathogenic Pulmonary Infection in Pediatric Patients with Cystic Fibrosis
por: Parsons, Emily, et al.
Publicado: (2020)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
por: Bock, A., et al.
Publicado: (2022)

Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation: A Single Center Experience of 196 Patients Over 30 Years
por: Vergote, Vibeke K. J., et al.
Publicado: (2022)

P1259: CHARACTERIZATION OF VENETOCLAX RESISTANCE IN CELL MODELS OF MANTLE CELL LYMPHOMA
por: Granau, A., et al.
Publicado: (2022)

P1113: PROGNOSTIC ROLE OF GENETIC ABNORMALITIES IN MANTLE CELL LYMPHOMA
por: Kleina, E., et al.
Publicado: (2022)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

P1246: DIFFERENTIAL ROLE OF MICROENVIRONMENT AND STROMAL-CELL INDUCED VENETOCLAX RESISTANCE IN MANTLE CELL LYMPHOMA
por: Andersen, P., et al.
Publicado: (2022)

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM
por: Wang, Y., et al.
Publicado: (2022)

P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB
por: Le Gouill, S., et al.
Publicado: (2022)

P1295: DECIPHERING THE ROLE OF MSI2 AS A REGULATOR OF MANTLE CELL LYMPHOMA STEM-LIKE PROPERTIES
por: Sureda-Gómez, M., et al.
Publicado: (2022)

P1214: CTPS1 ACTS AS A PROGNOSTIC BIOMARKER AND THERAPEUTIC TARGET IN MANTLE CELL LYMPHOMA
por: Ren, Yi-Min, et al.
Publicado: (2023)

P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA
por: Shah, B., et al.
Publicado: (2022)

P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY
por: Tivey, A., et al.
Publicado: (2022)

P1250: EU-SOX11CCND1: A NOVEL IMMUNOCOMPETENT MURINE MODEL OF MANTLE CELL LYMPHOMA
por: Brown, F., et al.
Publicado: (2022)

Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients
por: Morscio, Julie, et al.
Publicado: (2016)

Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [(18)F]FDG PET/CT
por: Montes de Jesus, Filipe, et al.
Publicado: (2021)

Correction to: Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients
por: Morscio, Julie, et al.
Publicado: (2018)

Targeting cyclin D1 for mantle cell lymphoma
por: Chen, Jingtao
Publicado: (2015)

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL
por: Morschhauser, F., et al.
Publicado: (2022)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
por: Haujir, A., et al.
Publicado: (2022)

P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2
por: Wang, M. L., et al.
Publicado: (2022)

P1207: SERIAL SINGLE-CELL PROFILING OF MANTLE CELL LYMPHOMA REVEALS FUNCTIONAL AND MOLECULAR CORRELATES OF RESISTANCE TO BTK INHIBITOR-INCLUSIVE TRIPLET THERAPY
por: Debaize, Lydie, et al.
Publicado: (2023)

P1279: INHIBITION OF PROTEIN KINASE CK2 AND BCL-2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH
por: Manni, S., et al.
Publicado: (2022)

P1089: ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA
por: Qu, Chang-Ju, et al.
Publicado: (2023)

P1291: REAL-WORLD DATA OF LONG-TERM SURVIVALS IN PATIENTS WITH MANTLE CELL LYMPHOMA WHO UNDERWENT STEM CELL TRANSPLANTATION
por: Won Baek, Dong, et al.
Publicado: (2023)

P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY
por: Shotton, Rohan, et al.
Publicado: (2023)

P1226: BTG2, A NOVEL TARGET OF MIR-17-92, REGULATES B CELL RECEPTOR SIGNALING IN MANTLE CELL LYMPHOMA
por: Kawaji-Kanayama, Yuka, et al.
Publicado: (2023)

P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL
por: Phillips, Tycel, et al.
Publicado: (2023)

1151 Geographic Distances Between Patients and Providers for Hepatitis C Virus Infection Testing
por: Klevens, Monina, et al.
Publicado: (2014)

SG-APSIC1151: ZeBox: A prophylactic device against airborne infection
por: Venkatraman, Srividya Janani, et al.
Publicado: (2023)

P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
por: Strati, Paolo, et al.
Publicado: (2023)

P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS
por: Steiner, R., et al.
Publicado: (2022)

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
por: Serna, Angel, et al.
Publicado: (2022)

P1244: AN AUTOMATED QUANTIFICATION ALGORITHM FOR EVALUATING TOTAL METABOLIC TUMOR VOLUME IN PATIENTS WITH FDG-AVID LYMPHOMAS USING A DEEP LEARNING MODEL
por: Xu, Tao, et al.
Publicado: (2023)

P1134: OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA POST-CBTK INHIBITOR THERAPY IN THE UNITED STATES AND JAPAN: A STUDY OF TWO REAL-WORLD DATABASES
por: Rai, S., et al.
Publicado: (2022)

P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
por: Sarkozy, Clementine, et al.
Publicado: (2023)

P1297: ABERRANT MYCN EXPRESSION DRIVES ONCOGENIC HIJACKING OF EZH2 AS A TRANSCRIPTIONAL ACTIVATOR IN PERIPHERAL T CELL LYMPHOMA
por: Vanden Bempt, M., et al.
Publicado: (2022)

1151. A Safer, More Effective Method for Cleaning and Disinfecting GI Endoscopic Procedure Rooms
por: Overholt, Bergein, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o3vgce53hhthdk6rp34stm5u0a